Pituitary Neoplasms
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.
Subtype terms (3)
More specific conditions that are subtypes of Pituitary Neoplasms in the MeSH hierarchy.
- ACTH-Secreting Pituitary Adenoma
1 drug approved
- Growth Hormone-Secreting Pituitary Adenoma
1 drug approved
- Prolactinoma
8 drugs (7 approved, 1 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (15)
Phase 3 trials (2)
Phase 2 trials (13)
Phase 1 trials (6)
Organizations
Organization Involved with Phase 4 Indications (10)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (13)
- Morphotek
- Endocyte
- National Cancer Institute (NCI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Burzynski Research Institute
- Cedars-Sinai Medical Center
- Cornell University
- Emory University
- Columbia University
- University of California, Los Angeles
- Memorial Sloan-Kettering Cancer Center
- Tiburio Therapeutics
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (12)